Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tango Therapeutics, Inc. (TNGX) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology company. Tango Therapeutics files a range of documents with the U.S. Securities and Exchange Commission that describe its financial condition, capital markets activities, and key corporate events, complementing its focus on discovering and developing precision cancer medicines using synthetic lethality.
Through Forms 8-K, Tango Therapeutics reports material events such as equity financings, at-the-market offering programs, and private placements, including underwriting agreements for registered offerings of common stock and pre-funded warrants, and securities purchase agreements for PIPE transactions. These filings often explain the intended use of proceeds, which the company has stated includes advancing its pipeline and supporting working capital and general corporate purposes, as well as expectations for its cash runway.
Other 8-K filings furnish press releases that summarize quarterly financial results and provide business highlights, including updates on clinical trials for vopimetostat (TNG462), TNG456, and TNG260. Filings also document corporate governance developments, such as leadership transitions, board appointments, and executive departures. Registration statements and prospectus supplements referenced in these filings outline the structure and terms of Tango Therapeutics’ capital raising activities.
On Stock Titan, users can review Tango Therapeutics’ SEC filings alongside AI-powered summaries that help explain the significance of each document. This includes quick insights into quarterly earnings releases (often furnished on Form 8-K), material financing agreements, at-the-market sales agreements, and other key disclosures. The filings page supports investors who want to understand how Tango Therapeutics funds its clinical-stage oncology programs, manages its capital structure, and reports material corporate events under SEC requirements.
Tango Therapeutics, Inc. (TNGX) received an amended Schedule 13G/A showing that EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman now report zero beneficial ownership of the company’s common stock. As of December 31, 2025, each reporting person lists 0 shares beneficially owned and a 0% stake, with no sole or shared voting or dispositive power. The filing confirms they own 5 percent or less of the class. The parties also state they are filing jointly but expressly disclaim being part of a group and disclaim beneficial ownership beyond any pecuniary interest.
Tango Therapeutics, Inc. received an amended Schedule 13G from TCG Crossover Fund II, TCG Crossover GP II, and Chen Yu reporting beneficial ownership of 13,521,839 shares of common stock, representing 9.99% of the class.
The position consists of 12,762,094 common shares and 759,745 shares underlying pre-funded warrants that are exercisable within 60 days of the statement. Additional pre-funded warrants for up to 1,066,666 shares are excluded because a 9.99% Beneficial Ownership Limitation prevents exercise above that threshold. Ownership is calculated using 134,593,998 shares outstanding as of October 28, 2025, plus the exercisable warrant shares. The filers state the securities are not held for the purpose of changing or influencing control of Tango.
Woodline Partners LP filed an amended beneficial ownership report showing a significant passive stake in Tango Therapeutics, Inc.. Woodline reports beneficial ownership of 10,072,225 shares of Tango common stock, representing 7.5% of the class.
The percentage is calculated using 134,677,094 shares of common stock outstanding as of November 1, 2025, as disclosed in a company registration statement. Woodline, a Delaware investment adviser, reports sole voting and dispositive power over these shares, which are directly held by Woodline Master Fund LP.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics. Woodline Master Fund has the right to receive dividends and sale proceeds from more than 5% of the common stock.
Tango Therapeutics, Inc. received an updated ownership report from Invus-affiliated investors and Raymond Debbane. As of December 31, 2025, Invus Public Equities directly held 7,068,444 common shares and Avicenna Life Sci Master Fund held 1,096,930 shares of Tango Therapeutics.
Through a chain of general partners and managing members, including Invus Public Equities Advisors, Invus Global Management, Siren, Avicenna GP and Ulys, Raymond Debbane may be deemed to beneficially own 8,165,374 shares, representing 6.1% of Tango’s common stock, based on 134,593,998 shares outstanding as of October 28, 2025. The reporting group certifies the shares were not acquired to change or influence control of the company.
Adage Capital Management, L.P. and affiliates report a 7.88% beneficial stake in Tango Therapeutics, Inc. They collectively hold 10,607,924 shares of Tango common stock, with shared voting and investment power and no sole authority reported.
The ownership percentage is based on 134,677,094 Tango shares outstanding as of November 1, 2025, as disclosed in a company registration statement. The investors state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics, Inc. filed an Amendment No. 4 to Schedule 13D/A reporting updated ownership by Third Rock Ventures entities. As of February 6, 2026, Third Rock Ventures IV, L.P. and its affiliated general partners reported shared voting and dispositive power over 6,374,574 shares of Tango common stock, representing approximately 4.74% of outstanding shares, based on 134,593,998 shares outstanding as of October 28, 2025. The amendment states that transactions described in Item 5(c) caused a decrease of over one percentage point in the aggregate ownership previously reported. These changes follow several open-market sales of Tango shares in January and February 2026.
Tango Therapeutics, Inc. received an amended Schedule 13G showing updated ownership by funds managed by Farallon Capital. As of the reporting date, the Farallon Funds hold 13,391,411 common shares and 2,159,792 pre-funded warrants, each warrant exercisable into one share.
The warrants are subject to a 9.99% Beneficial Ownership Limitation, so only 69,804 warrants are currently counted as exercisable within 60 days when calculating beneficial ownership. The amendment also records governance changes at Farallon: Avner A. Husen became a member/manager of the related general partners effective January 1, 2026, while Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles as of December 31, 2025, and may no longer be deemed beneficial owners. The filing is made on a passive basis under Rule 13d-1(c), with the group certifying the holdings are not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics Chief Financial Officer Daniella Beckman reported new equity awards and related tax sales. On February 2, 2026, she acquired 44,330 shares of common stock for $0, representing restricted stock units that vest in three tranches through February 2029, and received a stock option for 265,980 shares at an exercise price of $11.94 per share, vesting over four years.
On February 3, 2026, she sold 10,204 and 113 shares of common stock at weighted average prices of $12.2573 and $12.8971, respectively, under the company’s automatic “sell-to-cover” policy for tax withholding tied to RSU vesting. After these transactions, she held 184,297 shares of common stock and 265,980 stock options, all reported as directly owned.
Barbara Weber, Director and Executive Chair of Tango Therapeutics, Inc., reported multiple equity transactions. She acquired 37,522 shares of common stock on February 2, 2026 through restricted stock units that vest in full on February 1, 2027, subject to continued service.
On the same date she was granted a stock option for 222,132 shares at an exercise price of
Tango Therapeutics President of R&D Crystal Adam reported new equity awards and related tax sales of common stock. On February 2, 2026, she received 47,460 restricted stock units, each equal to one share, vesting 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service. She also received a stock option for 284,760 shares at an exercise price of $11.94, vesting 25% on January 1, 2027 and monthly thereafter for three years. To cover tax withholding from RSU vesting under the company’s sell-to-cover policy, she automatically sold 18,251 shares at a weighted average $12.2573 and 201 shares at a weighted average $12.8971 on February 3, 2026. After these transactions, she directly owned 187,218 common shares and 284,760 options.